Bioventus (NASDAQ:BVS) Announces Earnings Results, Beats Estimates By $0.02 EPS

Bioventus (NASDAQ:BVS) announced its quarterly earnings results on Thursday. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.02, FiscalAI reports. The firm had revenue of $157.90 million for the quarter. Bioventus had a return on equity of 29.99% and a net margin of 4.00%.

Here are the key takeaways from Bioventus’ conference call:

• Delivered a strong finish to 2025 with 10% organic revenue growth in Q4, Adjusted EBITDA up $8M to $37M and Adjusted EBITDA margin expanded ~490 bps to 23%, plus record quarterly cash from operations of ~ $38M (full-year cash from operations nearly $75M).
• 2026 guidance and investments target growth acceleration—management guided $600–$610M in revenue, $0.73–$0.77 adj. EPS, and $82–$87M cash from ops, while allocating ~$13M incremental investment to PNS, PRP, Ultrasonics and international to drive future revenue (PNS+PRP expected to contribute a minimum 200 bps in 2026).
• Strengthening capital structure—Q4 debt paydown of $29M left $294M outstanding and net leverage under 2.5x, with management expecting leverage <2.0x by end-2026, enabling lower interest expense and greater capital allocation optionality while targeting an ~20% Adjusted EBITDA margin in 2026.
• Near-term headwinds and assumptions—management expects Q1 to be the weakest quarter due to one fewer selling day and HA distributor inventory rebalancing, and foreign exchange drove an unplanned ~ $1M Q4 loss (~$3M+ YTD); guidance assumes no further USD fluctuations.
• Product/launch progress—pilot launches for PNS and PRP returned favorable physician and patient feedback (PNS trial and permanent solutions validated), and Ultrasonics will receive disproportionate investment (focus on spine) to expand adoption through sales, marketing, education, and evidence generation.

Bioventus Stock Down 7.6%

Bioventus stock opened at $8.41 on Friday. The stock has a market cap of $696.01 million, a P/E ratio of 25.48 and a beta of 0.78. Bioventus has a twelve month low of $5.81 and a twelve month high of $11.25. The company’s 50-day moving average price is $8.12 and its two-hundred day moving average price is $7.49. The company has a quick ratio of 1.14, a current ratio of 1.74 and a debt-to-equity ratio of 1.50.

Analysts Set New Price Targets

Several research analysts have recently commented on BVS shares. Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a research note on Wednesday. Barrington Research upgraded Bioventus to a “strong-buy” rating in a research note on Monday, February 9th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bioventus in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.